The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Fujifilm
Speakers' Bureau - Biogen (I); Genzyme (I); Ipsen; Merrimack; Novartis (I); Taiho Pharmaceutical; Teva (I)
A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc.
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Michael H. Veeder
No Relationships to Disclose
 
Jason J. Luke
Honoraria - Intellisphere, LLC
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Newlink Genetics; Novartis; Reflexion Medical; Syndax; Tempest Therapeutics
Research Funding - Abbvie; Boston Biomedical; Bristol-Myers Squibb; Celldex; Checkmate Pharmaceuticals; Corvus Pharmaceuticals; Delcath Systems; Five Prime Therapeutics; Genentech/Roche; Immunocore; Incyte; Macrogenics; MedImmune; Merck; Novartis; Palleon Pharmaceuticals; Pharmacyclics; Tesaro
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Novartis; Reflexion Medical
 
Jason Chandler
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen
Speakers' Bureau - Janssen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen
 
Ani Sarkis Balmanoukian
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck
 
Thomas J. George
Consulting or Advisory Role - Bayer; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pharmacyclics (Inst); Tesaro (Inst)
 
Pamela Munster
No Relationships to Disclose
 
Jordan Berlin
Honoraria - genentech; Nestle health science
Consulting or Advisory Role - Aduro Biotech; BeiGene; Celgene; Cornerstone Pharmaceuticals; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; Opsona Therapeutics; Pierre Fabre; Symphony Evolution
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Celgene; EMD Serono; Genentech/Roche; Nestle health science
Other Relationship - AstraZeneca; Symphony Evolution
 
Martin Gutierrez
Stock and Other Ownership Interests - COTA
Consulting or Advisory Role - Bayer; Karyopharm Therapeutics; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Foundation One Inc; Lilly; Merck
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Esanex (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst)
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Heather A. Wakelee
Honoraria - Novartis
Research Funding - ACEA Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Xcovery (Inst)
 
Selda Samakoglu
No Relationships to Disclose
 
Shanhong Guan
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Isaiah W. Dimery
Leadership - Pharmacyclics
Travel, Accommodations, Expenses - Pharmacyclics
 
Erkut Borazanci
No Relationships to Disclose